Chikungunya vaccine: PaxVax announces the initiation of Phase 2b Trial
by Press Release from Outbreak News Today on (#3NX7N)
PaxVax, a leading independent specialty vaccine company, announced today the enrollment of the first patient in its Phase 2b dose-finding trial of the chikungunya virus-like particle (VLP) vaccine, building upon a Phase 2a study by the National Institutes of Health (NIH) with 400 subjects. The Phase 2b study will enroll 400 subjects to evaluate multiple dosing regimens. PaxVax expects ["]
The post Chikungunya vaccine: PaxVax announces the initiation of Phase 2b Trial appeared first on Outbreak News Today.